human normal immunoglobulin


CSL Behring


Concise Prescribing Info
Human normal Ig
Replacement therapy in primary immunodeficiency syndromes eg, congenital agammaglobulinaemia & hypogammaglobulinaemia, common variable & severe combined immunodeficiency, Wiskott-Aldrich syndrome; myeloma or chronic lymphocytic leukemia w/ severe secondary hypogammaglobulinaemia & recurrent infections; childn w/ congenital AIDS & recurrent infections. Immune thrombocytopenia purpura (ITP) in childn or adult at high risk of bleeding or prior to surgical interventions to correct the platelet count, Guillain-Barre syndrome, Kawasaki disease. Allogeneic bone marrow transplantation.
Dosage/Direction for Use
Replacement therapy in primary immunodeficiency syndromes 0.4-0.8 g/kg followed by at least 0.2 g/kg every 3 wk. Replacement therapy in myelomas or chronic lymphocytic leukaemia w/ severe secondary hypogammaglobulinaemia & recurrent infections; replacement therapy in childn w/ congenital AIDS & recurrent infections 0.2-0.4 g/kg every 3-4 wk. Acute ITP 0.8-1 g/kg on day 1, may be repeated once w/in 3 days or 0.4 g/kg daily for 2-5 days. Guillain-Barre syndrome 0.4 g/kg daily over 5 days. Kawasaki disease 1.6-2 g/kg administered in divided doses over 2-5 days or 2 g/kg as a single dose. Allogeneic bone marrow transplantation Initially, 0.5 g/kg wkly commencing 7 days pre-transplant & continued 3 mth post-transplant.
Hypersensitivity to homologous Ig, particularly in IgA deficiency where the patient has anti-IgA antibodies. Hyperprolinaemia.
Special Precautions
Hypersensitivity. High rate of infusion; patients w/ hypo- or agammaglobulinaemia w/ or w/o IgA deficiency, 1st time receiving human normal Ig therapy or, when the human normal Ig is switched or a long interval since the previous infusion. Haemolytic anaemia, aseptic meningitis syndrome. Obese patients, preexisting risk factors for thrombotic events. Possibility or transmitting infective agents. Discontinue use in case of renal impairment. Pregnancy & lactation.
Adverse Reactions
Headache. Vomiting, nausea; back pain; chills, fatigue, pyrexia.
Drug Interactions
Decreased efficacy of attenuated live virus vaccine.
ATC Classification
J06BA - Immunoglobulins, normal human ; Used in passive immunizations.
Privigen soln for infusion 10%
100 mL x 1's;200 mL x 1's;50 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in